Items Tagged ‘Ovarian Cancer’

September 11th, 2017

Pass it On: It’s National Ovarian Cancer Awareness Month

By

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason for this decrease remains unknown. Ovarian cancer usually has no obvious symptoms but some […]

View full entry

Tags: awareness month, genetic testing, hereditary, News, Ovarian Cancer, prevention


May 3rd, 2017

Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms

By

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis are asymptomatic and only in more severe cases are these patients subjected to minimally invasive […]

View full entry

Tags: cancer risk, endometriosis, News, ovarian, Ovarian Cancer


April 25th, 2017

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial

By

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it to destroy ovarian cancer cells […]

View full entry

Tags: clinical trial, immunotherpay, News, Ovarian Cancer, precision medicine, vaccine


April 3rd, 2017

Niraparib Approved for Ovarian Cancer Maintenance Treatment

By

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based chemotherapy. Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor, but unlike other drugs in this class, it […]

View full entry

Tags: News, niraparib, Ovarian Cancer, parp


March 6th, 2017

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?

By

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial investigating immunotherapy for patients with advanced ovarian cancer. A new clinical study underway at Roswell Park Cancer Institute is […]

View full entry

Tags: Gut Flora, Microbiome, News, Ovarian Cancer


February 28th, 2017

Chemo-brain Among Women with Breast Cancer is Very Common

By

The largest study to date of a condition known as “chemo-brain” shows that women with breast cancer report it’s a substantial problem after chemotherapy for as long as six months after treatment, according to investigators at the Wilmot Cancer Institute. Scientists have known that cancer-related cognitive impairment, which includes problems with memory, attention, and processing […]

View full entry

Tags: Breast Cancer, chemobrain and chemotherapy side effects, News, Ovarian Cancer


December 20th, 2016

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer

By

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each year in the U.S. roughly 22,000 women are diagnosed with ovarian cancer and more […]

View full entry

Tags: fda, FoundationFocus™ CDxBRCA, News, Ovarian Cancer, Ovarian cancer BRCA mutation, Rubraca, Rucaparib, Stage II-IV Ovarian Cancer


November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

By

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


October 20th, 2016

Tesaro Provides Real Benefit to Ovarian Cancer Patients

By

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the […]

View full entry

Tags: 2016, BRCA mutation, ESMO, News, niraparib, Ovarian Cancer, parp, poly(ADP)-ribose polymerase, recurrent, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer, Tesaro


October 6th, 2016

FDA Warns Against Ovarian Cancer Screening Tests

By

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most treatable. Inaccurate tests however, can miss a cancer diagnosis when one is present or falsely […]

View full entry

Tags: false, Inaccurate results, News, Ovarian Cancer, prevention, screening, Screening/Prevention Ovarian Cancer, tests


September 6th, 2016

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

By

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer […]

View full entry

Tags: Breakthrough Therapy Designation, News, Ovarian Cancer, PARP1, PARP2, PARP3, Stage II-IV Ovarian Cancer


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


July 13th, 2016

Niraparib Improves Progression-Free Survival in Ovarian Cancer

By

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer, and is the fifth most common cause of cancer-related deaths among women. Since there are no generalized […]

View full entry

Tags: BRCA1, BRCA2, News, niraparib, NOVA trial, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen